Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14857108 | 0.74 | HRH4 (0.43) | HRH4CYP19A1HRH3CYP17A1CYP3A4 | |
| SCHEMBL3700407 | 0.74 | ALDH1A1 (0.37) | CYP19A1CYP3A4 | |
| SCHEMBL26052366 | 0.73 | HRH1 (0.42) | HRH4HRH3 | |
| SCHEMBL5500827 | 0.73 | CYP19A1 (0.39) | CYP19A1 | |
| SCHEMBL21554045 | 0.72 | CYP19A1 (0.30) | CYP19A1 | |
| SCHEMBL22096189 | 0.72 | HRH4 (0.37) | HRH4CYP19A1HRH3IDO1 | |
| SCHEMBL3695170 | 0.71 | CYP19A1 (0.39) | CYP19A1CYP3A4 | |
| SCHEMBL27922362 | 0.70 | CYP19A1 (0.38) | CYP19A1CYP3A4 | |
| SCHEMBL3707615 | 0.70 | ALDH1A1 (0.39) | CYP19A1CYP3A4 | |
| SCHEMBL22059382 | 0.69 | CYP19A1 (0.37) | CYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | HRH4 273/4885CYP19A1 4539/4885HRH3 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.